ARK Investment Management Adds $13M in Absci Corporation ($ABSI)
Key Points
- ARK Investment Management changed its Absci Corporation ($ABSI) stake by 9.36% last quarter, boosting to 13,726,169 shares worth $153.05 million.
- Wall Street's consensus rating on $ABSI is Strong Buy and an average price target of $13.89.
- $ABSI last traded around $11.15.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
ARK Investment Management increased its position in Absci Corporation ($ABSI) by 9.36% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 13,726,169 shares of Absci Corporation after buying 1,175,370 shares during the quarter. ARK Investment Management's holdings in Absci Corporation were worth $153.05 million as of its most recent filing.
Absci Corporation Stock Up 28.0%
Shares of Absci Corporation ($ABSI) traded around $11.15 on Saturday, up 28.0% for the day.
Absci Corporation Earnings
Analysts Set New Price Targets
About Absci Corporation
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Get Absci Corporation alerts
New 13F filings, insider trades, and analyst moves on $ABSI, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.